DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Raymond James Maintains Outperform on Bellicum Pharmaceuticals, Lowers Price Target to $17

Raymond James maintains Bellicum Pharmaceuticals (NASDAQ:BLCM) with a Outperform and lowers the price target from $40 to $17.

Benzinga · 03/13/2020 11:18

Raymond James maintains Bellicum Pharmaceuticals (NASDAQ:BLCM) with a Outperform and lowers the price target from $40 to $17.